Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Merger or Acquisition (March 2025)
17 slides from Zealand Pharma A/s's merger presentation, Mar 12, 2025
Slide 1: Global exclusive collaboration and license agreement with Roche
Global exclusive collaboration and license agreement with Roche Zealand Pharma March 12, 2025
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Phar
Slide 3: Agenda
Agenda Q&A Strategic rationale Petrelintide Financials Adam Steensberg David Kendall Henriette Wennicke Chief Executive Chief Medical Chief Financial Officer Officer Officer 3
Slide 4: Strategic rationale
Strategic rationale Adam Steensberg, President and Chief Executive Officer Global exclusive collaboration and license agreement with Roche - Zealand Pharma conference call presentation March 12, 2025 4
Slide 5: Transformative collaboration and license agreement to unlock the full potential of petrelintide
Transformative collaboration and license agreement to unlock the full potential of petrelintide True partnership agreement ✓ Shared vision for petrelintide as a future foundational therapy for weight management ✓ Co-development and co-commercialization (up to 50% in U.S. and Europe) Important synerg
Slide 6: Roche is the ideal partner to maximize the potential of petrelintide
Roche is the ideal partner to maximize the potential of petrelintide Leading development Global Extensive Shared vision capabilities commercial reach manufacturing network • Established teams in • Presence in over 150 • Strong commitment to CVRM, including diverse markets • Global manufacturing CVRM
Slide 7: The obesity pandemic represents one of the greatest healthcare challenges of our time
The obesity pandemic represents one of the greatest healthcare challenges of our time Early days in the evolution of this market… For 300,000 years, human beings maintained a relatively stable BMI… Eligible patients in the U.S. receiving ~2% prescriptions for weight loss therapy2 The obesity pandemi
Slide 8: Success of future weight-loss medications will be determined by differentiation on multiple fronts
Success of future weight-loss medications will be determined by differentiation on multiple fronts GLP-1 mono Examples of differentiation factors GLP-1-based GLP-1/GIP Unique non-incretin mechanisms, addressing quality of weight GLP-1/GCGa loss for weight maintenance (incl. preservation of muscle ma
Slide 9: Petrelintide
Petrelintide David Kendall, Chief Medical Officer Global exclusive collaboration and license agreement with Roche - Zealand Pharma conference call presentation March 12, 2025 9
Slide 10: We have a differentiated mid- to late-stage obesity pipeline
We have a differentiated mid- to late-stage obesity pipeline Petrelintidea Petrelintide/CT-388a Survodutideb Dapiglutide Long-acting Amylin + GLP-1/GIP Glucagon/GLP-1 GLP-1/GLP-2 amylin analog fixed-dose combination receptor dual agonist receptor dual agonist Ph2b initiation in obesity Ph3 programs
Slide 11: Petrelintide is a long-acting, potential best-in-class amylin analog designed with stability at neutral pH
Petrelintide is a long-acting, potential best-in-class amylin analog designed with stability at neutral pH Petrelintide is a 36-amino-acid acylated peptide, based on the peptide sequence of human amylin1 Long-acting amylin analog due to acylation (half-life of 10 days), suitable for once-weekly admi
Slide 12: Petrelintide has consistently shown best-in-class potential across early clinical trials to date
Petrelintide has consistently shown best-in-class potential across early clinical trials to date MAD trial Part 1 MAD trial Part 2 SAD trial1 (6-week study)2 (16-week study)3 % change in body weight % change in body weight % change in body weight from baseline at Day 7 from baseline at Week 6 from b
Slide 13: Our vision is to establish the leading amylin-based weight management franchise with petrelintide
Our vision is to establish the leading amylin-based weight management franchise with petrelintide Potential to address the unmet medical needs of the majority of people with overweight and obesity Unmet medical needs… …being targeted with petrelintide Petrelintide monotherapy as a foundational Alter
Slide 14: Financials
Financials Henriette Wennicke, Chief Financial Officer Global exclusive collaboration and license agreement with Roche - Zealand Pharma conference call presentation March 12, 2025 14
Slide 15: Key financial terms of collaboration
Key financial terms of collaboration Consideration to Profit share, royalties, Collaboration scope Zealand Pharma & other ✓ Petrelintide Upfront U.S. & Europe • $1,650 million in upfronta • 50 / 50 profit share 50/50 ✓ Petrelintide / CT-388 Outside U.S. & Europe fixed-dose combination Development mi
Slide 16: Petrelintide partnership is a step change to realize our vision
True partnership with co-development, co-commercialization, and 50/50 profit sharing in the U.S. and Europe, and shared vision for petrelintide as a future foundational therapy for weight management Accelerating and expanding the opportunities with petrelintide as stand-alone Petrelintide therapy an
Slide 17: Q&A
Q&A Zealand Pharma upcoming investor events • Barclays 26th Annual Global Healthcare Conference, Miami, March 12-13 • Zealand Pharma Annual General Meeting, March 27 • Kempen Life Sciences Conference, Amsterdam, April 2-3 • Zealand Pharma Q1 2025 Financial Results, May 8 • Bank of America Healthcare